Summary

We use the most thorough and iterative research technique available, with a primary focus on offering the most precise market projections and research data content to help you develop previously unheard-of levels of business acumen. The company's primary methods for qualitative market assessments and market segmentation are top-down and bottom-up techniques. We take pride in our ability to use data triangulation to examine the market from three key angles: primary data mining, a specific statistical model and framework, and primary source data validation.

We carefully choose our original raw market data for analysis from a vast collection of data that has been compiled in our repository, as well as from sets of trustworthy and validated websites, analyst evaluations, news announcements, whitepapers, and reputable paid databases. Trade journals and in-depth surveys are used to collaborate on technical data and trends. Verified sources are used to assess pricing trends and market dynamics.

We use particular data simulation models to get our market estimates and forecasts. These models are developed and tailored to match the unique needs of every study. They are nimble and adaptable. For the most part, we use a joint combination of technological analysis, economic tools, domain experience, and economic techniques to forecast and estimate the market. In general, we favor using a bottom-up method to assess the worldwide market and calculate the anticipated rate of growth.

To verify our hypotheses and the results we have gotten, we carry out in-depth primary interviews, which include phone conversations, in-person discussions, and targeted group discussions. Extensive primary research has been conducted to verify our figures and forecast. These interviews also provide us with an objective view of the market, important information on companies operating in various markets, and up-to-date business scenarios.

Transplant Diagnostics Market based on Product & Service:
• Instruments
• Reagents & Consumables
Transplant Diagnostics Market based on Screening Type:
• Pre-Transplant
• Post-Transplant
Transplant Diagnostics Market based on Organ Type:
• Kidney
• Liver
• Heart
• Lung
• Pancreas
Transplant Diagnostics Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
Based on the product and service, the transplant diagnostics market is divided into divisions for instruments, reagents, and consumables. In 2021, the global market was dominated by the reagents and consumables segment. The main characteristic of this market is the higher rate of consumption of these items across all applications and end-uses, as well as higher replacement rates despite lower costs. Purchase agreements for consumables and reagents are among the tactics used by producers of these kinds of diagnostic devices. Furthermore, the primary element expediting the acceptance of reagents and consumables is their recurring acquisition.

The rapid modernization and automation of diagnostic laboratories, the rise in the number of organ transplant procedures, and the outsourcing of research and development activities by pharmaceutical and biotechnology companies to independent reference laboratories are additional factors contributing to this segment's large share.

Pre- and post-transplant screening are included in the market segmentation for transplant diagnostics based on the type of screening. Pre-transplant revenue accounted for roughly 60–64 percent of the transplant diagnostics market in 2021, giving it the lion's share of the market. Pre-transplantation analysis techniques like these are used to make sure things run smoothly and safely. The adoption of technologically improved instruments at a rapid pace and rising physician awareness are two factors that are anticipated to propel growth in the upcoming years. Additionally, a growing elderly population that is more vulnerable to many chronic illnesses as a result of weakened immunity is one of the main causes driving the pre-transplant diagnostics market expansion for diagnostic applications.

Organ types that are included in the market segmentation of transplant diagnostics include kidney, liver, heart, lung, and pancreas. In 2021, the kidney segment accounted for the largest proportion of market revenue. The market is expected to increase in segments due to the rising number of kidney transplant surgeries and the government rules that encourage organ donations in key healthcare markets. The market for serological transplant diagnostics is seeing an increase in the use of kidney and liver transplants due to the growing prevalence of renal and liver failure among the elderly population. in particular in people who have long-term illnesses. According to publications titled Chronic Kidney Disease in India released by the American Society of Nephrology, the prevalence of CKD in India varies from 1% to 13%.

• This report illustrates the most vital attributes of the Transplant Diagnostics Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Transplant Diagnostics Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Transplant Diagnostics Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Transplant Diagnostics Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Product & Service: Market Size & Analysis
5.1. Overview
5.2. Instruments
5.3. Reagents & Consumables
6. Screening Type: Market Size & Analysis
6.1. Overview
6.2. Pre-Transplant
6.3. Post-Transplant
7. Organ Type: Market Size & Analysis
7.1. Overview
7.2. Kidney
7.3. Liver
7.4. Heart
7.5. Lung
7.6. Pancreas
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. HOLOGIC, INC. (U.S.)
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. BIOFORTUNA LIMITED (U.K.)
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. TAKARA BIO INC. (JAPAN)
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. ABBOTT (U.S.)
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. DIAGNÓSTICA LONGWOOD SL (SPAIN)
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. ADAPTIVE BIOTECHNOLOGIES (U.S.)
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. NANOSTRING TECHNOLOGIES, INC.(U.S.)
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. ARQUER DIAGNOSTICS LTD (U.K.)
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. F. ALTONA DIAGNOSTICS GMBH (GERMANY)
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. ELITECHGROUP (FRANCE)
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 2. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR REAGENTS & CONSUMABLES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 5. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR PRE-TRANSPLANT, 2021-2030 (USD BILLION)
TABLE 6. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR POST-TRANSPLANT AND OROPHARYNGEAL SWABS, 2021-2030 (USD BILLION)
TABLE 7. TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 8. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR KIDNEY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR LIVER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR HEART, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR LUNG, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. TRANSPLANT DIAGNOSTICS MARKET VALUE FOR PANCREAS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 15. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 17. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 18. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 19. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 20. U.S TRANSPLANT DIAGNOSTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 21. CANADA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 22. CANADA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 23. CANADA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 24. MEXICO TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 25. MEXICO TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 26. MEXICO TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 27. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 28. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 29. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 30. EUROPE TRANSPLANT DIAGNOSTICS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 31. GERMANY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 32. GERMANY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 33. GERMANY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 34. U.K TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 35. U.K TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 36. U.K TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 37. FRANCE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 38. FRANCE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 39. FRANCE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 40. ITALY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 41. ITALY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 42. ITALY TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 43. SPAIN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 44. SPAIN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 45. SPAIN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 46. ROE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 47. ROE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 48. ROE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 49. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 50. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 53. CHINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 54. CHINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 55. CHINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 56. INDIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 57. INDIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 58. INDIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 59. JAPAN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 60. JAPAN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 61. JAPAN TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 62. REST OF APAC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 63. REST OF APAC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 65. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 66. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 68. BRAZIL TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 69. BRAZIL TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 71. ARGENTINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 72. ARGENTINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 74. MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 75. MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 77. SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 78. SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 80. UAE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 81. UAE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 82. UAE TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 83. REST OF MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION)
TABLE 84. REST OF MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY SCREENING TYPE, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET VALUE, BY ORGAN TYPE, 2021-2030 (USD BILLION)
TABLE 86. HOLOGIC, INC. (U.S.): FINANCIALS
TABLE 87. HOLOGIC, INC. (U.S.): PRODUCTS & SERVICES
TABLE 88. HOLOGIC, INC. (U.S.): RECENT DEVELOPMENTS
TABLE 89. BIOFORTUNA LIMITED (U.K.): FINANCIALS
TABLE 90. BIOFORTUNA LIMITED (U.K.): PRODUCTS & SERVICES
TABLE 91. BIOFORTUNA LIMITED (U.K.): RECENT DEVELOPMENTS
TABLE 92. TAKARA BIO INC. (JAPAN): FINANCIALS
TABLE 93. TAKARA BIO INC. (JAPAN): PRODUCTS & SERVICES
TABLE 94. TAKARA BIO INC. (JAPAN): RECENT DEVELOPMENTS
TABLE 95. ABBOTT (U.S.): FINANCIALS
TABLE 96. ABBOTT (U.S.): PRODUCTS & SERVICES
TABLE 97. ABBOTT (U.S.): RECENT DEVELOPMENTS
TABLE 98. DIAGNÓSTICA LONGWOOD SL (SPAIN): FINANCIALS
TABLE 99. DIAGNÓSTICA LONGWOOD SL (SPAIN): PRODUCTS & SERVICES
TABLE 100. DIAGNÓSTICA LONGWOOD SL (SPAIN): RECENT DEVELOPMENTS
TABLE 101. ADAPTIVE BIOTECHNOLOGIES (U.S.): FINANCIALS
TABLE 102. ADAPTIVE BIOTECHNOLOGIES (U.S.): PRODUCTS & SERVICES
TABLE 103. ADAPTIVE BIOTECHNOLOGIES (U.S.): RECENT DEVELOPMENTS
TABLE 104. NANOSTRING TECHNOLOGIES, INC.(U.S.): FINANCIALS
TABLE 105. NANOSTRING TECHNOLOGIES, INC.(U.S.): PRODUCTS & SERVICES
TABLE 106. NANOSTRING TECHNOLOGIES, INC.(U.S.): DEVELOPMENTS
TABLE 107. ARQUER DIAGNOSTICS LTD (U.K.): FINANCIALS
TABLE 108. ARQUER DIAGNOSTICS LTD (U.K.): PRODUCTS & SERVICES
TABLE 109. ARQUER DIAGNOSTICS LTD (U.K.): RECENT DEVELOPMENTS
TABLE 110. F. ALTONA DIAGNOSTICS GMBH (GERMANY): FINANCIALS
TABLE 111. F. ALTONA DIAGNOSTICS GMBH (GERMANY): PRODUCTS & SERVICES
TABLE 112. F. ALTONA DIAGNOSTICS GMBH (GERMANY): RECENT DEVELOPMENTS
TABLE 113. ELITECHGROUP (FRANCE): FINANCIALS
TABLE 114. ELITECHGROUP (FRANCE): PRODUCTS & SERVICES
TABLE 115. ELITECHGROUP (FRANCE): RECENT DEVELOPMENTS